

Corinne Faivre-Finn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/295596/publications.pdf>

Version: 2024-02-01

243
papers

18,950
citations

23544

58
h-index

12933

131
g-index

249
all docs

249
docs citations

249
times ranked

16919
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 2342-2350.	13.9	2,150
2	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
3	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 664-672.	13.9	990
4	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	12.5	792
5	ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and) Tj ETQq1 1 0.784314 rgBT / Overlock 107	3.15	756
6	Small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 3.	18.1	560
7	Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. <i>Lancet, The</i> , 2016, 388, 2004-2014.	6.3	556
8	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
9	Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 36-42.	6.3	441
10	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology, The</i> , 2017, 18, 1116-1125.	5.1	415
11	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	0.6	410
12	Guidelines on the radical management of patients with lung cancer. <i>Thorax</i> , 2010, 65, iii1-iii27.	2.7	393
13	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.	0.5	328
14	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	0.5	323
15	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01,) Tj ETQq1 1 0.784314 rgBT / Overlock 107	5.1	318
16	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	0.6	308
17	European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5301-5310.	0.8	276
18	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	0.6	246

#	ARTICLE	IF	CITATIONS
19	Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 25-38.	0.4	240
20	Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptomsâ€”Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. <i>Journal of Clinical Oncology</i> , 2009, 27, 78-84.	0.8	240
21	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	0.6	210
22	Definition of Synchronous Oligometastatic Nonâ€”Small Cell Lung Cancerâ€”A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
23	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 1-10.	0.3	177
24	Targeting Hypoxia to Improve Nonâ€”Small Cell Lung Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2018, 110, 14-30.	3.0	177
25	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.3	168
26	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). <i>Annals of Oncology</i> , 2011, 22, 1154-1163.	0.6	165
27	British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. <i>Thorax</i> , 2018, 73, i1-i30.	2.7	157
28	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	3.1	151
29	Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. <i>Annals of Oncology</i> , 2014, 25, 1270-1283.	0.6	147
30	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 1-5.	0.3	141
31	Radiation dose to heart base linked with poorer survival in lung cancer patients. <i>European Journal of Cancer</i> , 2017, 85, 106-113.	1.3	136
32	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 104-114.	5.1	123
33	Colon cancer in France: evidence for improvement in management and survival. <i>Gut</i> , 2002, 51, 60-64.	6.1	115
34	Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. <i>European Radiology</i> , 2020, 30, 6241-6250.	2.3	115
35	The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 181-184.	0.6	114
36	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2020, 10, 158-173.	1.1	111

#	ARTICLE	IF	CITATIONS
37	Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	105
38	Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 344-352.	0.4	102
39	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <i>Annals of Oncology</i> , 2018, 29, 301-310.	0.6	98
40	Distributed learning on 20 000+ lung cancer patients – The Personal Health Train. <i>Radiotherapy and Oncology</i> , 2020, 144, 189-200.	0.3	97
41	LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. <i>British Journal of Radiology</i> , 2015, 88, 20150036.	1.0	96
42	Colorectal adenocarcinoma in patients under 45 years of age. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 380-387.	0.7	92
43	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	2.9	92
44	R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. <i>Frontiers in Oncology</i> , 2017, 7, 59.	1.3	90
45	Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1624-1635.	0.5	89
46	Magnetic Resonance Imaging–Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1057-1060.	0.4	83
47	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1328.	1.3	81
48	Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. <i>Cancer Treatment Reviews</i> , 2012, 38, 626-640.	3.4	76
49	High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2014, 15, e620-e624.	5.1	76
50	Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype. <i>Lung Cancer</i> , 2020, 146, 197-208.	0.9	74
51	Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. <i>Lung Cancer</i> , 2017, 108, 150-153.	0.9	70
52	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	1.3	69
53	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1627-1643.	0.5	67
54	Management of Small Cell Lung Cancer. <i>Drugs</i> , 2012, 72, 471-490.	4.9	63

#	ARTICLE	IF	CITATIONS
55	Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1598-1608.	0.5	63
56	Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1073-1081.	0.4	62
57	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
58	The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). <i>Radiotherapy and Oncology</i> , 2019, 131, 166-173.	0.3	59
59	Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice. <i>Lung Cancer</i> , 2009, 66, 150-156.	0.9	58
60	Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. <i>Journal of Hepatology</i> , 1998, 29, 802-806.	1.8	57
61	Management of stage I and II nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1600764.	3.1	56
62	Magnetic resonance imaging in precision radiation therapy for lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 689-707.	1.3	56
63	Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2018, 8, e020690.	0.8	56
64	Radical treatment of non-small cell lung cancer during the last 5 years. <i>European Journal of Cancer</i> , 2013, 49, 1555-1564.	1.3	54
65	Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. <i>Annals of Oncology</i> , 2019, 30, 1114-1120.	0.6	54
66	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.3	53
67	Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1200-1208.	0.8	52
68	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3818-3829.	3.2	51
69	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1-24.	0.6	50
70	Evidence of improving survival of patients with rectal cancer in France: a population based study. <i>Gut</i> , 1999, 44, 377-381.	6.1	49
71	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 216-230.	0.5	49
72	Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. <i>Annals of Oncology</i> , 2017, 28, 2923-2931.	0.6	46

#	ARTICLE	IF	CITATIONS
73	Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, e185335.	3.4	46
74	The European initiative for quality management in lung cancer care. <i>European Respiratory Journal</i> , 2014, 43, 1254-1277.	3.1	44
75	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 442-447.	2.9	43
76	New radiotherapy approaches in locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2014, 50, 525-534.	1.3	43
77	Post-treatment lymphocytopenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 115-119.	0.3	42
78	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
79	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.4	40
80	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer – Evidence from a phase II trial. <i>Lung Cancer</i> , 2012, 76, 72-77.	0.9	39
81	Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 682-693.	3.3	39
82	Residual Setup Errors Towards the Heart After Image Guidance Linked With Poorer Survival in Lung Cancer Patients: Do We Need Stricter IGRT Protocols?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 434-442.	0.4	39
83	Radiotherapy for extensive stage small-cell lung cancer – Authors' reply. <i>Lancet</i> , The, 2015, 385, 1292-1293.	6.3	38
84	Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 353-359.	1.9	37
85	Modern Management of Small-Cell Lung Cancer. <i>Drugs</i> , 2007, 67, 2135-2152.	4.9	37
86	Protocol for the CONVERT trial – Concurrent ONce-daily VErus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. <i>BMJ Open</i> , 2016, 6, e009849.	0.8	37
87	Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 63-71.	0.5	37
88	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 867-875.	0.4	37
89	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. <i>Lung Cancer</i> , 2014, 83, 117-125.	0.9	35
90	BTS guideline for the investigation and management of malignant pleural mesothelioma. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000266.	1.2	35

#	ARTICLE	IF	CITATIONS
91	A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. <i>Acta Oncologica</i> , 2018, 57, 226-230.	0.8	35
92	Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study. <i>Lancet Regional Health - Europe</i> , The, 2021, 7, 100144.	3.0	35
93	Radiotherapy for lung cancer in the elderly. <i>Lung Cancer</i> , 2010, 68, 129-136.	0.9	34
94	Lung function evaluation before surgery in lung cancer patients: how are recent advances put into practice? A survey among members of the European Society of Thoracic Surgeons (ESTS) and of the Thoracic Oncology Section of the European Respiratory Society (ERS). <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2009, 9, 925-931.	0.5	33
95	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
96	18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1296-1305.	0.5	32
97	Lung cancer after treatment for breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 1184-1192.	5.1	30
98	Dose escalation in lung cancer: have we gone full circle?. <i>Lancet Oncology</i> , The, 2015, 16, 125-127.	5.1	30
99	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30
100	Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. <i>BMJ Open</i> , 2016, 6, e010589.	0.8	28
101	The clinical utility of circulating tumour cells in patients with small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 409-417.	1.3	28
102	Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study. <i>PLoS Medicine</i> , 2022, 19, e1003904.	3.9	28
103	Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature. <i>Annals of Oncology</i> , 2015, 26, 278-288.	0.6	27
104	SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer considered to be at higher risk of complications from surgical resection. <i>European Respiratory Journal</i> , 2020, 56, 2000118.	3.1	27
105	Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small-cell lung cancer?: Table 1. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013, 17, 845-853.	0.5	26
106	Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 617681. "ERS/ESTS CLINICAL GUIDELINES ON FITNESS FOR RADICAL THERAPY IN LUNG CANCER PATIENTS (SURGERY) Tj FTQq1 1 0.784314 rgB"	1.3	26
107	VARELA, M. LICKER, M.K. FERGUSON, C. FAIVRE-FINN, R.M. HUBER, E.M. CLINI, T. WIN, D. DE RUYSSCHER AND L. GOLDMAN ON BEHALF OF THE EUROPEAN RESPIRATORY SOCIETY AND EUROPEAN SOCIETY OF THORACIC SURGEONS JOINT TASK FORCE ON FITNESS FOR RADICAL THERAPY. <i>EUR RESPIR J</i> 2009; 34: 17-41. <i>European Respiratory Journal</i> , 2009, 34, 782-782.	3.1	25
108	Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 244-249.	0.3	25

#	ARTICLE	IF	CITATIONS
109	Effect of age, period of diagnosis and birth cohort on large bowel cancer incidence in a well-defined French population, 1976-1995. <i>European Journal of Cancer Prevention</i> , 2002, 11, 529-534.	0.6	24
110	Management of Unresectable Stage III Non-Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment. <i>Clinical Lung Cancer</i> , 2008, 9, 92-101.	1.1	24
111	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. <i>EBioMedicine</i> , 2015, 2, 841-850.	2.7	24
112	Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. <i>BMJ Open</i> , 2016, 6, e010457.	0.8	24
113	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1378-1385.	0.8	24
114	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
115	CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8504-8504.	0.8	24
116	Understanding the Differences Between Bayesian and Frequentist Statistics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1076-1082.	0.4	24
117	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 89-95.	0.3	23
118	Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. <i>Clinical Lung Cancer</i> , 2005, 7, 23-29.	1.1	22
119	Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 117-125.	0.3	19
120	Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1075-1085.	0.5	19
121	Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. <i>Radiotherapy and Oncology</i> , 2000, 57, 137-142.	0.3	18
122	Is tumour sphericity an important prognostic factor in patients with lung cancer?. <i>Radiotherapy and Oncology</i> , 2020, 143, 73-80.	0.3	18
123	The Routine Clinical Implementation of Electronic Patient-reported Outcome Measures (ePROMs) at The Christie NHS Foundation Trust. <i>Clinical Oncology</i> , 2021, 33, 761-764.	0.6	18
124	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. <i>Lung Cancer</i> , 2011, 74, 75-9.	0.9	17
125	Recent developments in limited stage small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S147-S152.	1.3	17
126	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019, 136, 145-147.	0.9	17

#	ARTICLE	IF	CITATIONS
127	Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 294-297.	0.5	17
128	Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1341-1348.	0.4	17
129	Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8005-8005.	0.8	17
130	Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. <i>Lung Cancer</i> , 2021, 162, 96-105.	0.9	17
131	Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): Solid evidence or "œno-go". <i>Radiotherapy and Oncology</i> , 2013, 109, 178-179.	0.3	16
132	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	1.1	16
133	Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2014, 6, 328-35.	0.6	16
134	Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence. <i>Journal of Clinical Oncology</i> , 2015, 33, 2930-2931.	0.8	15
135	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 61-66.	0.9	15
136	Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer. <i>British Journal of Radiology</i> , 2014, 87, 20130653.	1.0	14
137	Data Mining Identifies the Base of the Heart as a Dose-Sensitive Region Affecting Survival in Lung Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S48-S49.	0.4	14
138	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.3	14
139	Thoracic radiotherapy in small cell lung cancer—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2059-2070.	1.3	14
140	Traditional Phase 1 and 2 Studies in Thoracic Radiation Oncology Should Be Abandoned. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 487-489.	0.4	13
141	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020, 149, 84-88.	0.3	13
142	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer — Decision criteria in routine practise. <i>Radiotherapy and Oncology</i> , 2020, 150, 26-29.	0.3	13
143	Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). <i>Clinical Oncology</i> , 2017, 29, 707-710.	0.6	12
144	A method to combine target volume data from 3D and 4D planned thoracic radiotherapy patient cohorts for machine learning applications. <i>Radiotherapy and Oncology</i> , 2018, 126, 355-361.	0.3	12

#	ARTICLE	IF	CITATIONS
145	The impact of baseline shifts towards the heart after image guidance on survival in lung SABR patients. <i>Radiotherapy and Oncology</i> , 2020, 152, 183-188.	0.3	12
146	Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020. <i>Radiotherapy and Oncology</i> , 2022, 172, 118-125.	0.3	12
147	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.3	11
148	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021, 153, 165-170.	0.9	11
149	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.3	11
150	Improving care for patients with lung cancer in the UK. <i>Thorax</i> , 2013, 68, 1181-1185.	2.7	10
151	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	0.9	10
152	Quantitative evaluation of 4D Cone beam CT scans with reduced scan time in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2019, 136, 64-70.	0.3	10
153	Protecting the Heart: A Practical Approach to Account for the Full Extent of Heart Motion in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1082-1090.	0.4	10
154	Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5051s-5056s.	3.2	9
155	Treatment of limited small cell lung cancer: an old or new challenge?. <i>Current Opinion in Oncology</i> , 2011, 23, 158-162.	1.1	9
156	Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 137, 71-76.	0.3	9
157	The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance. <i>British Journal of Radiology</i> , 2019, 92, 20180988.	1.0	9
158	Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study. <i>BMJ Open</i> , 2019, 9, e019903.	0.8	9
159	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. <i>Radiotherapy and Oncology</i> , 2020, 145, 45-48.	0.3	9
160	Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 152, 177-182.	0.3	9
161	Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). <i>Radiotherapy and Oncology</i> , 2021, 160, 78-81.	0.3	9
162	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	1.1	9

#	ARTICLE	IF	CITATIONS
163	Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?. Radiotherapy and Oncology, 2021, 164, 183-195.	0.3	9
164	Evaluation of Prognostic and Predictive Models in the Oncology Clinic. Clinical Oncology, 2022, 34, 102-113.	0.6	9
165	Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. Journal of Thoracic Oncology, 2022, 17, 961-973.	0.5	9
166	Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. Lung Cancer, 2012, 77, 532-536.	0.9	8
167	Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer. Expert Review of Anticancer Therapy, 2017, 17, 555-561.	1.1	8
168	Effect of accurate heart delineation on cardiac dose during the CONVERT trial. British Journal of Radiology, 2017, 90, 20170036.	1.0	8
169	ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. European Respiratory Journal, 2018, 52, 1800610.	3.1	8
170	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1653-1665.	1.3	8
171	Optimising use of 4D-CT phase information for radiomics analysis in lung cancer patients treated with stereotactic body radiotherapy. Physics in Medicine and Biology, 2021, 66, 115012.	1.6	8
172	A multi-centre dosimetry audit on advanced radiotherapy in lung as part of the Isotoxic IMRT study. Physics and Imaging in Radiation Oncology, 2017, 4, 17-21.	1.2	7
173	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e159-e170.	1.8	7
174	MRI and CBCT for lymph node identification and registration in patients with NSCLC undergoing radical radiotherapy. Radiotherapy and Oncology, 2021, 159, 112-118.	0.3	7
175	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer, 2022, 166, 84-93.	0.9	7
176	Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy. Radiotherapy and Oncology, 2022, 172, 126-133.	0.3	7
177	Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer. Radiotherapy and Oncology, 2017, 122, 159-162.	0.3	6
178	The CONVERT Trial: Interpretation, Journey and Lessons Learnt. Clinical Oncology, 2017, 29, 811-813.	0.6	6
179	Benefit of using motion compensated reconstructions for reducing inter-observer and intra-observer contouring variation for organs at risk in lung cancer patients. Radiotherapy and Oncology, 2018, 126, 333-338.	0.3	6
180	In Regard to Zhang et al. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1179-1180.	0.4	6

#	ARTICLE	IF	CITATIONS
181	Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 197-199.	0.5	6
182	Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. <i>Lung Cancer</i> , 2022, 169, 94-101.	0.9	6
183	In Regard to Koshy et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 945-946.	0.4	5
184	Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View. <i>Clinical Oncology</i> , 2017, 29, 1-2.	0.6	5
185	Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 475-477.	0.5	5
186	Predictive value of vascular calcification identified in 4D planning CT of lung cancer patients treated with stereotactic body radiation therapy. <i>Physica Medica</i> , 2020, 78, 173-178.	0.4	5
187	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	0.9	5
188	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. <i>Manchester lung cancer group. Lung Cancer</i> , 2011, 73, 338-344.	0.9	4
189	Is it time to convert the frequency of radiotherapy in small-cell lung cancer? Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e556.	5.1	4
190	Results from a clinical trial evaluating the efficacy of real-time body surface visual feedback in reducing patient motion during lung cancer radiotherapy. <i>Acta Oncologica</i> , 2018, 57, 211-218.	0.8	4
191	Automated gross tumor volume contour generation for large-scale analysis of early-stage lung cancer patients planned with 4D-CT. <i>Medical Physics</i> , 2021, 48, 724-732.	1.6	4
192	Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice. <i>Cancer Treatment and Research Communications</i> , 2018, 17, 18-22.	0.7	3
193	Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e325-e329.	1.1	3
194	Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
195	B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration. <i>Journal of Thoracic Oncology</i> , 2007, 2, S338.	0.5	2
196	International Multicenter Randomized Study on Thoracic Radiation Therapy (RT) in Extensive Stage Small Cell Lung Cancer (ES-SCLC): Patterns of Disease Recurrence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S3-S4.	0.4	2
197	Whole brain radiotherapy for non-small cell lung cancer Authors' reply. <i>Lancet</i> , The, 2017, 389, 1395-1396.	6.3	2
198	OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S263.	0.5	2

#	ARTICLE	IF	CITATIONS
199	CONVERTed or not: what are the barriers to implementing the evidence? â€œ Author's reply. Lancet Oncology, The, 2017, 18, e628.	5.1	2
200	The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. Technical Innovations and Patient Support in Radiation Oncology, 2018, 7, 11-16.	0.6	2
201	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncology, 2021, 17, 1165-1184.	1.1	2
202	Radial Data Mining to Identify Densityâ€™Dose Interactions That Predict Distant Failure Following SABR. Frontiers in Oncology, 2022, 12, 838155.	1.3	2
203	O-90 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable advanced non-small cell lung cancer (NSCLC) â€™ A British thoracic oncology group (BTOG) trial. Lung Cancer, 2003, 41, S29.	0.9	1
204	D1-01: Prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer (ED-SCLC) after response to chemotherapy (EORTC 08993-22993): Quality of life (QoL) results.. Journal of Thoracic Oncology, 2007, 2, S389.	0.5	1
205	OA05.06 Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial. Journal of Thoracic Oncology, 2017, 12, S262-S263.	0.5	1
206	Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?â€™In Reply. JAMA Oncology, 2019, 5, 1229.	3.4	1
207	Less is more in radiotherapy target volume planning: lessons from the PET-plan trial. Lancet Oncology, The, 2020, 21, 481-483.	5.1	1
208	Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer. Lancet Oncology, The, 2021, 22, e220.	5.1	1
209	D1-02: Initial results from an intergroup phase III trial evaluating two different doses of prophylactic cranial irradiation (PCI) in patients with limited small cell cancer (SCLC) in complete remission (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212). Journal of Thoracic Oncology, 2007, 2, S389-S390.	0.5	1
210	Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC. International Journal of Radiation Oncology Biology Physics, 2021, 111, S91.	0.4	1
211	Demystifying Cardiac Dose in RTOG-0617. International Journal of Radiation Oncology Biology Physics, 2021, 111, S125.	0.4	1
212	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. International Journal of Radiation Oncology Biology Physics, 2022, 112, 265-270.	0.4	1
213	Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more. Annals of Translational Medicine, 2020, 8, 1114-1114.	0.7	1
214	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. European Journal of Cancer, Supplement, 2005, 3, 41-50.	2.2	0
215	Small Cell Lung Cancer (SCLC); any progress?. European Journal of Cancer, Supplement, 2007, 5, 398-399.	2.2	0
216	Respiratory Intrafraction Motion is an Important Source of Error in Radiotherapy to Oesophago-gastric Junction (OG) Cancers. International Journal of Radiation Oncology Biology Physics, 2007, 69, S280.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Efficacy of Positron Emission Tomography Staging for Small-Cell Lung Cancer: A Systematic Review and Cost Analysis in the Australian Setting. <i>Journal of Thoracic Oncology</i> , 2012, 7, e25.	0.5	0
218	Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 99-104.	2.2	0
219	Outcomes of Elderly Patients (≥70 Yo) with Advanced Non-Small Cell Lung Cancer (Nslc): a Multi-Institutional Analysis. <i>Annals of Oncology</i> , 2014, 25, iv442.	0.6	0
220	Cancers bronchiques non À petites cellules localement avancÃ©s : quelle radiothÃ©rapie en 2014 ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 421-430.	0.0	0
221	PO-0656: Effect of accurate heart outlining on radiation dose to the heart - the CONVERT Trial experience. <i>Radiotherapy and Oncology</i> , 2015, 115, S319-S320.	0.3	0
222	EP-1527: Early results from a clinical trial of visual feedback from dynamic optical surface sensing in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2015, 115, S833-S834.	0.3	0
223	PO-0660: A survey of current lung radiotherapy treatment techniques used during the CONVERT Trial. <i>Radiotherapy and Oncology</i> , 2015, 115, S321-S322.	0.3	0
224	PO-1119 Suitability of lung margins following analysis of set up data within a multi-national lung trial. <i>Radiotherapy and Oncology</i> , 2015, 115, S606-S607.	0.3	0
225	PO-0663: Lung V5 does not predict for lung toxicity after fixed-beam intensity modulated radiotherapy (IMRT) for lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, S323-S324.	0.3	0
226	Stereotactic body radiotherapy for central lung tumours: <i>Author reply</i>. <i>British Journal of Radiology</i> , 2015, 88, 20150532.	1.0	0
227	OC-0257: A Bayesian network model for acute dysphagia prediction in the clinic for NSCLC patients. <i>Radiotherapy and Oncology</i> , 2016, 119, S118-S119.	0.3	0
228	MTE05.01 Where is the Place of Surgery for N2 Disease?. <i>Journal of Thoracic Oncology</i> , 2017, 12, S152-S154.	0.5	0
229	P2.05-058 Blood Biomarkers of Inflammation, Tumor Burden and Proliferation Predict Radiotherapy Response and Toxicity in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1067-S1068.	0.5	0
230	MA13.11 Investigating the Feasibility of Establishing a Prospective Cohort of Lung Cancer Patients Following Radiotherapy with Curative Intent. <i>Journal of Thoracic Oncology</i> , 2017, 12, S421.	0.5	0
231	Response to a Request for Clarification Regarding the Advanced Radiotherapy Technologies Network (ART-NET). <i>Clinical Oncology</i> , 2018, 30, 391-393.	0.6	0
232	Reply to G. Zalcman et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2694-2695.	0.8	0
233	Author's Reply to the: Letter to the Editor. <i>Journal of Thoracic Oncology</i> , 2019, 14, e63-e64.	0.5	0
234	Cancers bronchiques de stade III: rÃ©le de lâ€™onco-radiothÃ©rapeute. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 278-289.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Cancers bronchiques de stade III : rôle de l'immunothérapie onco-radiothérapeutique. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S97-2S108.	0.0	0
236	Prise en charge des cancers bronchiques non à petites cellules oligométastatiques. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S109-2S120.	0.0	0
237	Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013. International Journal of Radiation Oncology Biology Physics, 2021, 111, e468-e469.	0.4	0
238	Treatment of Limited-Stage Disease in Older Patients: The Role of Thoracic Radiotherapy and Prophylactic Cranial Irradiation. , 2013, , 223-232.		0
239	How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer?. Translational Cancer Research, 2017, 6, S446-S447.	0.4	0
240	Clinical guidelines on diagnosis and management of patients with malignant pleural mesothelioma (part 1). Pulmonologiya, 2018, 28, 531-557.	0.2	0
241	Letter to the Editor: Increasing PET Use in Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, xxxixb.	2.3	0
242	Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more. Annals of Translational Medicine, 2020, 8, 1114.	0.7	0
243	Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC. Journal of Thoracic Oncology, 2022, 17, e55-e56.	0.5	0